- Companies
- MicroPort NeuroTech
MicroPort NeuroTech Revenue, Valuation, Funding & Investors
MicroPort NeuroTech is valued at $1.8B as of November 2021, a 31.3x multiple on its last reported $56M revenue.
Last MicroPort NeuroTech valuation
$1.8B
Undisclosed stage · Nov 2021
Last MicroPort NeuroTech funding round
$150M
Undisclosed stage · Nov 2021
MicroPort NeuroTech revenue
$56M
Undisclosed stage · Nov 2021
Key investors in MicroPort NeuroTech
CICC Healthcare Investment Fund
Huayi Capital
About MicroPort NeuroTech
MicroPort NeuroTech is a Shanghai-based neurovascular specialist founded in 2012 that develops stents for cerebrovascular diseases. Its WILLIS Intracranial Stent Graft System treats wide-neck aneurysms, while APOLLO and Tubridge devices reconstruct vessels. The company supplies over 500 hospitals in China with retrievable stents and flow diverters. MicroPort NeuroTech exports to Asia and Europe, focusing on stroke prevention therapies.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Revenue
$56M (Nov 2021)
Valuation
$1.8B (Nov 2021)
Sectors
MicroPort NeuroTech Valuation
MicroPort NeuroTech is currently valued at $1.8B, based on its undisclosed-stage round in November 2021.
The $150M round included Huayi Capital and CICC Healthcare Investment Fund.
MicroPort NeuroTech valuation by funding round
| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Nov 2021 | Undisclosed stage | $1.8B | 31.3x |
MicroPort NeuroTech Revenue
MicroPort NeuroTech's latest recorded revenue is $56M, as of its undisclosed-stage round in November 2021. At a $1.8B valuation, that implies a 31.3x revenue multiple.
MicroPort NeuroTech revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Nov 2021 | $56M | $1.8B | 31.3x | Undisclosed stage |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
MicroPort NeuroTech Funding History
MicroPort NeuroTech has raised a total of $150M across 1 funding round.
MicroPort NeuroTech funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2021 | Undisclosed stage | Huayi Capital; CICC Healthcare Investment Fund | $150M | $1.8B | MicroPort NeuroTech Limited (also referred to as Minimally Invasive Brain Science™ or MicroPort NeuroTech), a subsidiary of MicroPort Scientific Corporation (00853.HK), is a leading Chinese company in the neurointerventional medical device industry, focusing on innovative solutions for cerebrovascular diseases. It is the top Chinese player and among the top 5 globally, with 5 CE Markings, products in 18 overseas countries, and FDA, CE, and MDFS approved commercialized products. The company completed a US$150 million equity financing round on November 11, 2021, introducing strategic investors including CICC Capital (CICC Healthcare Investment Fund), Huayi Capital, Bohua Capital, Runkun Tianlu, and Tongxin Investment. The post-money valuation reached approximately $1.75 billion USD (equivalent to 11.2 billion yuan), positioning it as a leader in neurointervention market capitalization. This round followed prior convertible bonds subscribed by Belin Capital for $70 million. MicroPort NeuroTech maintains strong profitability in its neurovascular devices business, with group-level neurovascular revenue at $59.1 million in 2021, up 72.5% year-over-year, though specific revenue for NeuroTech alone is not broken out separately. The financing supports ongoing innovation, including an HKEx IPO application in progress at the time. MicroPort NeuroTech has a portfolio of 30 commercialized products and candidates since its first approval in 2004. The parent company's neurovascular segment showed rapid growth driven by market penetration and new launches, benefiting from normalization of surgeries post-epidemic. |
Who has invested in MicroPort NeuroTech?
2 investors have backed MicroPort NeuroTech across its funding rounds, including CICC Healthcare Investment Fund and Huayi Capital.
MicroPort NeuroTech Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 2 MicroPort NeuroTech investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialMicroPort NeuroTech Competitors
MicroPort NeuroTech competitors include listed companies like Jafron Biomedical, Poly Medicure, Qingdao Baheal Medical and Immunocore Holdings, and private ones like Rakuten Medical and Meril Life.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $300M | $123M | $1.8B | 5.2x | ||
| Private | - | - | $1.7B | - | ||
| Private | - | - | $1.8B | - | ||
| Publicly listed | $196M | $59M | $1.8B | 8.1x | ||
| Publicly listed | $1.1B | $139M | $1.8B | 1.9x | ||
| Publicly listed | $400M | ($20M) | $1.7B | 2.8x |
MicroPort NeuroTech Public Comps
MicroPort NeuroTech is still privately-owned, but its public comps include SKAN Group, Cofoe Medical, Embla Medical, Jafron Biomedical, Poly Medicure, Qingdao Baheal Medical, Edge Medical, LeMaitre Vascular, Immunocore Holdings and Mehow Innovative.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $406M | $43M | 4.5x | 3.9x | 42.0x | 28.5x | |||
| $505M | $89M | 2.9x | 2.4x | 16.2x | 15.0x | |||
| $929M | $187M | 2.4x | 2.2x | 11.9x | 10.9x | |||
| $300M | $123M | 5.4x | 5.2x | 13.2x | 11.2x | |||
| $196M | $59M | 9.0x | 8.1x | 30.1x | 33.2x | |||
| $1.1B | $139M | 1.9x | 1.9x | 15.1x | 16.8x | |||
| $68M | ($10M) | 22.9x | 14.3x | (153.6x) | 241.6x | |||
| $250M | $91M | 6.5x | 6.1x | 18.0x | 19.5x | |||
This data is available for Pro users. Sign up to see all MicroPort NeuroTech competitors and their valuation data. Start Free Trial | ||||||||
Common questions about MicroPort NeuroTech
| When was MicroPort NeuroTech founded? | MicroPort NeuroTech was founded in 2012. |
| Where is MicroPort NeuroTech headquartered? | MicroPort NeuroTech is headquartered in Shanghai, China. |
| Is MicroPort NeuroTech publicly listed? | No, MicroPort NeuroTech is a private, VC-backed company. |
| What is MicroPort NeuroTech's valuation? | MicroPort NeuroTech was last valued at $1.8B in its undisclosed-stage round in November 2021. |
| How much funding has MicroPort NeuroTech raised? | MicroPort NeuroTech has raised $150M across 1 funding round. |
| What was MicroPort NeuroTech's last funding round? | MicroPort NeuroTech's last funding round was a $150M undisclosed-stage round in November 2021. |
| Who are MicroPort NeuroTech's investors? | MicroPort NeuroTech's investors include Huayi Capital and CICC Healthcare Investment Fund. |
| What is MicroPort NeuroTech's revenue? | MicroPort NeuroTech's latest recorded revenue is $56M (November 2021). |
| What is MicroPort NeuroTech's revenue multiple? | MicroPort NeuroTech's latest valuation implies a 31.3x revenue multiple ($1.8B valuation on $56M of revenue). |
| Which companies are comparable to MicroPort NeuroTech? | Companies comparable to MicroPort NeuroTech include Jafron Biomedical, Rakuten Medical, Meril Life, Poly Medicure, Qingdao Baheal Medical and Immunocore Holdings. |
See companies similar to MicroPort NeuroTech
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




